TP53 and neoplasm: Preclinical studies have shown that pharmacological inhibition of SIRT1 restores p53 acetylation and sensitizes gastrointestinal tumor cells to oxidative stress-induced apoptosis, suggesting that SIRT1 acts as a redox-responsive regulator of tumor progression in gastrointestinal malignancies [56,112].